TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

TuHURA Biosciences (NASDAQ:HURA) announced executive participation in two investor events in March 2026. Dr. James Bianco, president and CEO, will present a webcast at the Citizens Life Science Conference on March 10, 2026 at 4:00 pm ET.

TuHURA will also be available for 1x1 investor meetings at the Leerink Global Healthcare Conference on March 11, 2026. Registration links and a live/archived webcast are available via TuHURA's investor events page.

TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

Citizens Life Science Conference
Date: Tuesday, March 10, 2026
Time: 4:00 pm ET
Links: To register and view presentation, click HERE. A live and archived webcast of the presentation will also be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.

Leerink Global Healthcare Conference
Date: Wednesday, March 11, 2026
Time: TuHURA will be available to meet 1x1 with investors
Links: To request a meeting, please contact your Leerink representative

About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda^® (pembrolizumab) compared to Keytruda^® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences-302696268.html

SOURCE TuHURA Biosciences, Inc.

FAQ

When will TuHURA (HURA) present at the Citizens Life Science Conference?

TuHURA will present at the Citizens Life Science Conference on March 10, 2026 at 4:00 pm ET. According to the company, a live and archived webcast will be available on TuHURA's investor website for registered viewers, and the registration link is provided in the conference listing.

What is TuHURA's (HURA) schedule for the Leerink Global Healthcare Conference on March 11, 2026?

TuHURA will be available for one-on-one investor meetings at the Leerink Global Healthcare Conference on March 11, 2026. According to the company, meeting requests must be routed through a Leerink representative to schedule 1x1 discussions with management during the conference.

How can investors access TuHURA (HURA) presentations and webcasts in March 2026?

Investors can access TuHURA presentations via live and archived webcasts on the company's investor relations website. According to the company, registration links are posted in event listings and archived videos will remain available on the TuHURA events page for a limited time.

Who from TuHURA (HURA) will speak at the March investor events?

Dr. James Bianco, TuHURA's president and CEO, will present March 10 and meet investors March 11. According to the company, Bianco's sessions include a webcast presentation March 10 and 1x1 investor meetings March 11 on the company's investor events page online.

Will TuHURA's (HURA) March presentations include clinical data about the Phase 3 program?

The presentations are investor-focused and may discuss TuHURA's Phase 3 immuno-oncology program and clinical progress. According to the company, specific data inclusion is not detailed in the notice; investors should view the webcast or request meetings for details from management.